ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for risk out of >500 occurrences
421954 occurrences (No.40 in the rank) during 5 years in the PubMed. [cache]
340) Analysis of ctDNA status could be utilized as a predictor of risk stratification for recurrence and to monitor the effectiveness of adjuvant chemotherapy.
* CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
- Adjuvant chemotherapy has reduced the risk of tumor recurrence and improved survival in patients with resected colorectal cancer. Potential utility of circulating tumor DNA (ctDNA) prior to and post surgery has been reported across various solid tumors. We initiated a new type of adaptive platform trials to evaluate the clinical benefits of ctDNA analysis and refine precision adjuvant therapy for resectable colorectal cancer, named CIRCULATE-Japan including three clinical trials. The GALAXY study is a prospectively conducted large-scale registry designed to monitor ctDNA for patients with clinical stage II to IV or recurrent colorectal cancer who can undergo complete surgical resection. The VEGA trial is a randomized phase III study designed to test whether postoperative surgery alone is noninferior to the standard therapy with capecitabine plus oxaliplatin for 3 months in patients with high-risk stage II or low-risk stage III colon cancer if ctDNA status is negative at week 4 after curative surgery in the GALAXY study. The ALTAIR trial is a double-blind, phase III study designed to establish the superiority of trifluridine/tipiracil as compared with placebo in patients with resected colorectal cancer who show circulating tumor-positive status in the GALAXY study. Therefore, CIRCULATE-Japan encompasses both "de-escalation" and "escalation" trials for ctDNA-negative and -positive patients, respectively, and helps to answer whether measuring ctDNA postoperatively has prognostic and/or predictive value. Our ctDNA-guided adaptive platform trials will accelerate clinical development toward further precision oncology in the field of adjuvant therapy. Analysis of ctDNA status could be utilized as a predictor of risk stratification for recurrence and to monitor the effectiveness of adjuvant chemotherapy. ctDNA is a promising, noninvasive tumor biomarker that can aid in tumor monitoring throughout disease management.
=>1.損害の恐れ, 危険, 冒険, リスク, 2.危険にさらす, 3.敢えてする, 被保険者, 被保険物, 危険にさらす,
賭けてみる
Overview of noun risk
The noun risk has 4 senses (first 2 from tagged texts)
1. (4) hazard, jeopardy, peril, risk, endangerment -- (a source of danger; a possibility of
incurring loss or misfortune; "drinking alcohol is a health hazard")
2. (2) risk, peril, danger -- (a venture undertaken without regard to possible loss or injury; "he
saw the rewards but not the risks of crime"; "there was a danger he would do the wrong thing")
3. risk, risk of infection -- (the probability of becoming infected given that exposure to an
infectious agent has occurred)
4. risk, risk of exposure -- (the probability of being exposed to an infectious agent)
Overview of verb risk
The verb risk has 2 senses (first 2 from tagged texts)
1. (8) risk, put on the line, lay on the line -- (expose to a chance of loss or damage; "We risked
losing a lot of money in this venture"; "Why risk your life?"; "She laid her job on the line when
she told the boss that he was wrong")
2. (2) gamble, chance, risk, hazard, take chances, adventure, run a risk, take a chance -- (take a
risk in the hope of a favorable outcome; "When you buy these stocks you are gambling")
--- WordNet end ---